Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 138Breast Neoplasms 95Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms, Male 6Advanced Breast Cancer 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Osteoporosis 2Leiomyoma 2Infertility 2Advanced Prostate Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Sarcopenia 1Radiation Injuries 1Primary Ovarian Insufficiency 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Osteitis Deformans 1Myofibroma 1Lymphatic Metastasis 1Kidney Diseases 1Inflammatory Breast Neoplasms 1

Interventions

bicalutamide 5enzalutamide 4exemestane 2darolutamide 2abiraterone 2pembrolizumab 1ostarine 1nilutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Prophylactic Mastectomy 1Prednisolone 1Panobinostat 1Mifepristone 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Docetaxel 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × Goserelin × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡